Efficacy and safety of olmesartan medoxomil-amlodipine besylate tablets (Sevikar?) in older patients with essential hypertension: Subgroup analysis from the Sevikar study

作者全名："Cui, Zhaoqiang; Qiu, Zhaohui; Cheng, Wenli; Hu, Wei; Ma, Genshan; Cai, Xiaojun; Jin, Yafei; Zhao, Yi; He, Liqun; Li, Ying; Bu, Peili; Chen, Xiaoping; Wang, Ruxing; Chen, Lin; Dong, Peng; Feng, Liuliu; Han, Xuebin; Hong, Mei; Hou, Yinglong; Liao, Minlei; Wang, Mingliang; Wang, Xiaoyan; Xie, Jianhong; Xu, Yawei; Wang, Zhenxing; Huang, Kai; Li, Yongle; Li, Dongsheng; Ji, Xiaojun; Huang, Jing; Wang, Jun; Fang, Danhong; Wang, Jian'an; Tang, Lijiang; Liu, Yingwu; Fu, Guosheng; Du, Juan; Wang, Ling; Liu, Mengqi; Ge, Junbo"

作者地址："[Cui, Zhaoqiang; Ge, Junbo] Fudan Univ, Zhongshan Hosp, Dept Cardiol, Shanghai 200032, Peoples R China; [Qiu, Zhaohui] Shanghai Tongren Hosp, Dept Cardiol, Shanghai 200050, Peoples R China; [Cheng, Wenli] Capital Med Univ, Beijing Anzhen Hosp, Dept Cardiol, Beijing 100029, Peoples R China; [Hu, Wei] Cent Hosp Minhang Dist, Dept Cardiol, Shanghai 201199, Peoples R China; [Ma, Genshan] Southeast Univ, Zhongda Hosp, Dept Cardiol, Nanjing 210009, Jiangsu, Peoples R China; [Cai, Xiaojun] Jinan Cent Hosp, Dept Cardiol, Jinan 250013, Shandong, Peoples R China; [Jin, Yafei] Sun Yat sen Univ, Affiliated Hosp 1, Dept Cardiol, Guangzhou 510062, Guangdong, Peoples R China; [Zhao, Yi] Dalian Jinzhou First Peoples Hosp, Dept Cardiol, Dalian 116199, Liaoning, Peoples R China; [He, Liqun] Wuhan 1 Hosp, Dept Cardiol, Wuhan 430030, Hubei, Peoples R China; [Li, Ying] Shanghai East Hosp, Dept Cardiol, Shanghai 200120, Peoples R China; [Bu, Peili] Shandong Univ, Qilu Hosp, Dept Cardiol, Jinan 250063, Shandong, Peoples R China; [Chen, Xiaoping] Sichuan Univ, West China Hosp, Dept Cardiol, Chengdu 610044, Sichuan, Peoples R China; [Wang, Ruxing] Wuxi Peoples Hosp, Dept Cardiol, Wuxi 214023, Jiangsu, Peoples R China; [Chen, Lin] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Cardiol, Guangzhou 510630, Guangdong, Peoples R China; [Dong, Peng] Beijing Aviat Gen Hosp, Dept Cardiol, Beijing 100123, Peoples R China; [Feng, Liuliu] Shidong Hosp, Dept Cardiol, Shanghai 200090, Peoples R China; [Han, Xuebin] Shanxi Cardiovasc Hosp, Shanxi Cardiovasc Dis Inst, Dept Cardiol, Taiyuan 030024, Shanxi, Peoples R China; [Hong, Mei] Nanjing Med Univ, Affiliated Hosp 2, Dept Cardiol, Nanjing 210003, Jiangsu, Peoples R China; [Hou, Yinglong] Shandong First Med Univ, Affiliated Hosp 1, Dept Cardiol, Jinan 250014, Shandong, Peoples R China; [Hou, Yinglong] Shandong Prov Qianfoshan Hosp, Jinan 250014, Shandong, Peoples R China; [Liao, Minlei] Shanghai Gen Hosp, Dept Cardiol, Baoshan Branch, Shanghai 201999, Peoples R China; [Wang, Mingliang] Shanghai Putuo Dist Peoples Hosp, Dept Cardiol, Shanghai 200060, Peoples R China; [Wang, Xiaoyan] Jiang Nan Univ, Dept Cardiol, Hosp Affiliated, Wuxi 214043, Jiangsu, Peoples R China; [Xie, Jianhong] Zhejiang Prov Peoples Hosp, Dept Cardiol, Hangzhou 314408, Zhejiang, Peoples R China; [Xu, Yawei] Shanghai Tenth Peoples Hosp, Dept Cardiol, Shanghai 200072, Peoples R China; [Wang, Zhenxing] Jiangsu Prov Hosp Chinese Med, Dept Cardiol, Nanjing 210004, Jiangsu, Peoples R China; [Huang, Kai] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Cardiol, Wuhan 430073, Hubei, Peoples R China; [Li, Yongle] Tianjin Med Univ, Dept Cardiol, Gen Hosp, Tianjin 300052, Peoples R China; [Li, Dongsheng] Wuhan Third Hosp, Dept Cardiol, Wuhan 430074, Hubei, Peoples R China; [Ji, Xiaojun] Wenzhou Cent Hosp, Dept Cardiol, Wenzhou 325099, Zhejiang, Peoples R China; [Huang, Jing] Chongqing Med Univ, Affiliated Hosp 2, Dept Cardiol, Chongqing 400010, Peoples R China; [Wang, Jun] Jingan Dist Cent Hosp Shanghai, Dept Cardiol, Shanghai 200040, Peoples R China; [Fang, Danhong] Wenzhou Med Univ, Affiliated Hosp 1, Dept Cardiol, Wenzhou 325015, Zhejiang, Peoples R China; [Wang, Jian'an] Zhejiang Univ, Affiliated Hosp 2, Dept Cardiol, Sch Med, Hangzhou 310003, Zhejiang, Peoples R China; [Tang, Lijiang] Zhejiang Hosp, Dept Cardiol, Hangzhou 310013, Zhejiang, Peoples R China; [Liu, Yingwu] Tianjin Third Cent Hosp, Dept Cardiol, Tianjin 300170, Peoples R China; [Fu, Guosheng] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Cardiol, Sch Med, Hangzhou 310020, Zhejiang, Peoples R China; [Du, Juan; Wang, Ling; Liu, Mengqi] Daiichi Sankyo China Holdings Co Ltd, Med Dept, Shanghai 200040, Peoples R China; [Ge, Junbo] Fudan Univ, Zhongshan Hosp, Dept Cardiol, 180 Fenglin Rd, Shanghai 200032, Peoples R China"

通信作者："Ge, JB (通讯作者)，Fudan Univ, Zhongshan Hosp, Dept Cardiol, 180 Fenglin Rd, Shanghai 200032, Peoples R China."

来源：EXPERIMENTAL AND THERAPEUTIC MEDICINE

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:001144011800001

JCR分区：Q3

影响因子：2.4

年份：2024

卷号：27

期号：2

开始页：　

结束页：　

文献类型：Article

关键词：olmesartan medoxomil-amlodipine besylate tablet; essential hypertension; blood pressure target; adverse event

摘要："Essential hypertension is a notable threat for the older (age, >= 65 years) population. However, to the best of our knowledge, a real-world study assessing olmesartan medoxomil-amlodipine besylate (OM-AML) tablets in older Chinese patients with essential hypertension has not been performed. Therefore, the present study aimed to evaluate the efficacy and safety of OM-AML tablets in these patients. A total of 463 older Chinese patients with essential hypertension treated with OM-AML (20/5 mg) tablets (Sevikar (R)) were analyzed in a prospective, single-arm, multi-center, real-world study. Seated systolic blood pressure (SeSBP) and seated diastolic blood pressure (SeDBP) at baseline, and at week (W)4 and W8 after OM-AML tablet administration were measured. The mean +/- standard error change of SeSBP/SeDBP was -10.3 +/- 0.8/-4.6 +/- 0.5 and -12.5 +/- 0.8/-5.6 +/- 0.5 mmHg at W4 and W8, respectively. At W4, 74.1 and 26.8% of patients achieved BP target according to the China and American Heart Association (AHA) criteria, while at W8, 78.0 and 38.7% of patients reached these BP targets accordingly. Finally, 76.5 and 80.5% of patients achieved BP response at W4 and W8, respectively. Furthermore, home-measured SeSBP and SeDBP were significantly decreased from W1 to W8 (both P<0.001). Additionally, the satisfaction of both patients and physicians was elevated at W8 compared with at W0 (both P<0.001). The medication possession rate from baseline to W4 and W8 was 95.5 and 92.5%. The most common drug-associated adverse events by system organ classes were nervous system disorder (4.5%), vascular disorder (2.8%), and general disorder and administration site conditions (2.6%), which were generally mild. In conclusion, OM-AML tablets may be considered effective and safe in lowering BP, enabling the achievement of guideline-recommended BP targets in older Chinese patients with essential hypertension."

基金机构："Daiichi Sankyo (China) Holdings Co., Ltd, Shanghai, China"

基金资助正文："The present study was supported by Daiichi Sankyo (China) Holdings Co., Ltd, Shanghai, China."